Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs The Vita Coco Company Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $295.89 (market cap $8.04B), while The Vita Coco Company Inc trades at $76.37 (market cap $4.23B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and The Vita Coco Company Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | COCO | |
|---|---|---|
Market Cap | $8.04B | $4.23B |
Sector | Health | Technology |
52-Week High | $339.75 | $84.02 |
52-Week Low | $241.71 | $32.30 |
Enterprise Value | $7.85B | $4.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
COCO trades at $74.635, up 4.53% today, with a bullish technical signal and strong earnings momentum after beating Q1 2026 EPS estimates. The company reported 37% YoY revenue growth in Q1 2026, with management raising full-year guidance. Analysts maintain a $78.00 consensus price target, with 60% recommending Buy. Key support lies at $72, with resistance at $76.
Outlook remains positive driven by international expansion and dominant market position, but elevated valuation multiples pose risks. Upside depends on sustained execution against raised guidance, while any earnings miss or margin pressure could trigger volatility. The stock offers growth exposure but requires monitoring of competitive and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
